Wegovy and Mounjaro reimbursed in France: conditions, dates, prescription.
This article provides general information on access to care in France, and is not medical advice. It does not replace the judgement of your physician. Access conditions are changing rapidly: confirm the situation at the time of your prescription.
TL;DR
From 15 June 2026, Wegovy (semaglutide 2.4 mg) and Mounjaro (tirzepatide) — the first GLP-1 receptor agonists reimbursed in France for obesity — are covered at 65% by French National Health Insurance (Assurance Maladie) for adults living with class III obesity (massive) (BMI ≥ 40 kg/m²) or class II obesity (severe) (BMI ≥ 35 kg/m² with a comorbidity), following six months of documented failure of well-conducted nutritional management (weight loss < 5%). Initial prescription is restricted to specialist structures (CSO, CHU, SMR). Outside the French reimbursement framework, these GLP-1 RA treatments remain prescribable on a private basis in France for BMI ≥ 30 (or ≥ 27 with a comorbidity).
1. The timeline and key figures
Two ministerial orders published in the French Official Journal (JORF) on 28 May 2026 list Wegovy and Mounjaro on the schedule of reimbursable medicines1. Reimbursement takes effect on 15 June 2026. The announcement was made by Minister of Health Stéphanie Rist at the specialist obesity centre of the Pitié-Salpêtrière hospital (AP-HP). For the first time in France, GLP-1 receptor agonists enter the scope of obesity reimbursement — a milestone in the medical management of the disease.
The price negotiated between the French state and Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) is around €300 per month, broadly in line with current pharmacy prices. With 65% reimbursement, the monthly out-of-pocket cost for the patient is approximately €105, to which €1 in prescription levy is added. A qualifying complementary health insurance plan can cover this remaining amount.1
2. Who is eligible for reimbursement in 2026
The ministerial orders of 28 May define two target populations, consistent with the Haute Autorité de Santé (HAS) opinion of 18 December 2025 (France's national health authority) and the Transparency Committee opinion of 20 February 2026.23
Wegovy (semaglutide) is a GLP-1 mono-agonist; Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist. These two molecules from the GLP-1 analogue family share the same French reimbursement framework and the same eligibility criteria in France.
Criterion 1: BMI and comorbidities
- Class III obesity (massive): BMI ≥ 40 kg/m², no comorbidity required.
- Class II obesity (severe): BMI ≥ 35 kg/m² with at least one comorbidity (for example: type 2 diabetes, hypertension, obstructive sleep apnoea, established cardiovascular disease, metabolic steatohepatitis).
Criterion 2: documented failure of nutritional management
Under the French reimbursement rules, prescription is only reimbursed as second-line treatment, after six months of "well-conducted nutritional management" whose objective outcome is a weight loss of less than 5% of baseline body weight. This period must be documented by clinicians: dietetic consultations, adapted physical activity programme, behavioural support, monitoring of clinical measurements.3
Criterion 3: adjunct to a reduced-calorie diet and increased physical activity
The ministerial orders specify that the prescription must be "in addition to a reduced-calorie diet and increased physical activity". In other words: the medication does not replace the lifestyle pathway. It is added to it.
3. The prescription pathway in practice
To limit potential misuse and ensure an appropriate clinical framework, initial prescription is strictly regulated.
- First prescription: restricted to physicians practising in a specialist obesity centre (CSO), a university hospital (CHU), or a rehabilitation centre (SMR).
- Mandatory documentation: reimbursement is "subject to the prescriber providing information on the circumstances and indications of the prescription" — in other words, precise clinical documentation is required.1
- Renewal: under the terms set by the ministerial order, the prescription may subsequently be renewed by other prescribers (confirm with your referring physician and pharmacist).
- Six-month review: the HAS recommends a systematic review of the treatment response, with the possibility of discontinuation if weight loss remains < 5%.2
4. What it will actually cost
Before the ministerial order of 28 May, the price of Wegovy and Mounjaro was freely set by the manufacturers: patients were spending around €300 per month out of pocket since late 2024.1 With 65% coverage:
- Negotiated monthly cost: approximately €300 (the official price does not reflect the confidential discounts agreed by manufacturers).
- Amount covered by French National Health Insurance: ~€195/month.
- Patient out-of-pocket cost: ~€105/month + €1 prescription levy.
- With a qualifying complementary health insurance plan: the out-of-pocket cost may be covered in full or in part, depending on your policy.
For patients who cannot be treated under the French reimbursement framework, the market price in France remains around €300 per month, borne entirely by the patient or their complementary insurer.
5. If you are not eligible for reimbursement in France
In France, reimbursement targets class II and class III obesity: it does not apply to everyone living with obesity. But this does not mean these GLP-1 treatments are out of reach.
Outside the reimbursed framework, Wegovy and Mounjaro — the two GLP-1 receptor agonists available in France for obesity — remain prescribable by a specialist or general practitioner for:
- patients with a BMI ≥ 30 kg/m²;
- or patients with a BMI ≥ 27 kg/m² with at least one comorbidity (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea syndrome, etc.).
In these situations, the treatment cost remains entirely the patient's responsibility (~€300/month) or that of their complementary insurer. Prescription must always be combined with dietary measures and increased physical activity.
6. Why the six months prior matter as much as the prescription
The six-month period required by the French reimbursement framework before prescription is not an administrative formality. It is the foundation on which the effectiveness of treatment subsequently rests.
- Clinically: Wegovy and Mounjaro, like all GLP-1 receptor agonists, are effective only within a holistic care framework, as an adjunct to a nutritional pathway and physical activity. A GLP-1 RA without lifestyle change leads to a weaker response, a more pronounced rebound effect on stopping, and lower long-term persistence.
- Regulatorily: without rigorous documentation of the six months, the physician cannot attest to "failure of well-conducted nutritional management", an explicit condition of reimbursement.
- In practice: dietetic consultations, adapted physical activity programme, behavioural support, monitoring of weight and clinical measurements — this is sustained work, not a box-ticking exercise completed at the end of the period.
The role of a digital tool in this support: to structure these six months, document what happens day to day (nutrition, activity, sleep, how you feel), and provide clinicians with the objective clinical data to support an informed therapeutic decision.
7. Why between-consultation support remains essential
Once the prescription has been obtained, the main risk is not the average efficacy of the molecule — that is well established. The risk is early discontinuation of treatment.
In the largest US claims analysis to date (Rodriguez et al., JAMA Network Open 2025, n > 125,000), approximately 65% of adults without diabetes who started a GLP-1 for weight had discontinued it by 12 months; a significant fraction stopped within the first six months.5 See our article: why half of GLP-1 patients stop.
The drivers of discontinuation are well documented: poorly managed digestive tolerability during dose escalation, a sense of isolation between consultations, the mental load of treatment, and loss of motivation when a plateau sets in. None of these are resolved in a 15-minute consultation — all of them play out between appointments.
8. Why Boli was designed for this moment
The French ministerial orders of 28 May 2026 have two direct consequences: rigorous documentation of the care pathway becomes an explicit condition of reimbursement, and between-consultation support remains the primary determinant of real-world effectiveness. Boli was designed, from the outset, for both of these requirements — and for the two populations these reimbursement criteria create.
Patients eligible for reimbursement in France
- Documenting the six prior months. Boli structures your daily routine (nutrition, activity, sleep, how you feel, clinical measurements) and provides clinicians with the objective clinical data that attests to "well-conducted nutritional management" within the meaning of the ministerial order. Not a form filled in at the end of the period: a continuous, exportable record.
- Optimising the treatment response. Once the prescription has been obtained, Boli provides between-consultation support — managing side effects during dose escalation, adherence, lifestyle adjustments, and clinical alerts relayed to the physician. Half of patients on GLP-1 RA stop within the year.5 Not with continuous support.
Patients outside reimbursement in France
- Maximising the return on investment. When Wegovy or Mounjaro remains your responsibility (~€300/month, sometimes more), a structured lifestyle pathway and rigorous follow-up multiply the effect of the molecule. Without support, you are paying for the medication — not the result.
- Securing every month invested. Documenting what works, identifying what is holding you back, adjusting with your physician before a cycle of poorly managed side effects or a premature plateau sets in. At this level of personal expenditure, every month without a clear response costs twice over.
9. Frequently asked questions
From what date are Wegovy and Mounjaro reimbursed in France?
Reimbursement by French National Health Insurance (Assurance Maladie) takes effect from 15 June 2026, following two ministerial orders published in the French Official Journal (JORF) on 28 May 2026.
What is the reimbursement rate in France?
In France, the rate is 65% of the negotiated price, meaning approximately €195 covered out of a monthly cost of around €300. The out-of-pocket amount (~€105 + €1 prescription levy) may be covered by a qualifying complementary health insurance plan.
Who is eligible for reimbursement of Wegovy and Mounjaro in France?
Adults with class III obesity (massive) (BMI ≥ 40 kg/m², no comorbidity required) or class II obesity (severe) (BMI ≥ 35 kg/m² with at least one comorbidity), following documented failure of well-conducted nutritional management over 6 months (weight loss < 5%).
Who can prescribe Wegovy or Mounjaro to benefit from reimbursement in France?
Initial prescription is restricted to physicians practising in a specialist structure: a specialist obesity centre (CSO), a university hospital (CHU), or a rehabilitation centre (SMR). Renewal may subsequently be handled by other prescribers under the terms set by the ministerial order.
What if I do not meet the French reimbursement criteria?
Wegovy and Mounjaro remain available on prescription for patients with a BMI ≥ 30, or BMI ≥ 27 with at least one comorbidity, as an adjunct to dietary measures and increased physical activity. In these situations, the cost of treatment remains the patient's responsibility or that of their complementary insurer.
What does "six months of well-conducted nutritional management" mean under the French framework?
A period of structured and documented nutritional support (dietetic consultations, adapted physical activity programme, behavioural support), with an objective outcome of less than 5% weight loss from baseline. This documentation is a prerequisite for reimbursement eligibility in France.
Are Wegovy and Mounjaro GLP-1 medications?
Yes. Wegovy (semaglutide) is a GLP-1 mono-agonist: it mimics the GLP-1 hormone that regulates satiety and blood glucose. Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist: it targets two gut receptors. Both belong to the GLP-1 analogue family, now at the heart of anti-obesity medication.
Is there a difference between Wegovy and Mounjaro for reimbursement in France?
Both ministerial orders apply comparable eligibility criteria. The choice between these two GLP-1 receptor agonists is a clinical decision for the physician based on the patient's clinical phenotype (cardiovascular, sleep, diabetes, etc.) and expected tolerability. See our article: Wegovy vs Mounjaro: what the real-world data shows.
In France, is Mounjaro reimbursed for obesity, or only for diabetes?
The French ministerial order of 28 May 2026 lists Mounjaro (tirzepatide) for reimbursement in the obesity indication, under the same criteria as Wegovy. Mounjaro also remains reimbursed in its established type 2 diabetes indication.
What if I am already taking Wegovy or Mounjaro at my own expense in France?
Discuss with your physician the possibility of switching to the French reimbursed framework after 15 June: your eligibility will depend on the criteria above, and in particular on documentation of your initial nutritional pathway.
Boli Care does not prescribe and does not substitute your physician. The app helps you structure your pathway, document what happens day to day, and provide clinicians with objective clinical data — valuable during the six prior months, and essential between consultations once treatment begins.
Early accessReferences
- Ministerial orders of 28 May 2026 listing Wegovy (semaglutide) and Mounjaro (tirzepatide) on the schedule of reimbursable pharmaceutical specialities for social security beneficiaries and for collective use. French Official Journal (JORF), 28 May 2026. Available on Légifrance — JORF of 28 May 2026 (direct search: "Wegovy", "Mounjaro"). Official announcement by Minister of Health Stéphanie Rist at the specialist obesity centre of the Pitié-Salpêtrière hospital (AP-HP), 28 May 2026 — AFP / France 24, La Croix.
- Haute Autorité de Santé (HAS). Opinion n°2025.0075/AC/SEM of 18 December 2025 of the HAS Board on the priority sub-populations among patients eligible for Wegovy (semaglutide) and Mounjaro (tirzepatide). has-sante.fr.
- Haute Autorité de Santé (HAS). WEGOVY (semaglutide) - Obesity - Transparency Committee opinion, 20 February 2026. Favourable opinion for reimbursement only in adults with an initial BMI ≥ 35 kg/m² following failure of well-conducted nutritional management (< 5% weight loss at six months). has-sante.fr.
- Aron-Wisnewsky J, Disse E, et al. Position paper of the GCC-CSO/FORCE on anti-obesity medication (AOM). Médecine des Maladies Métaboliques 2025/2026. doi:10.1016/j.mmm.2025.10.003.
- Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open 2025;8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349. PMID 39888616.